AbstractRelevance. The development of medical and pharmaceutical technologies has allowed ensuring the quality of life of children even with severe chronic diseases, but often the treatment of such children is associated with polypharmacy. Objective is to assess the risks of drug interactions in children with polypharmacy. Materials and methods. The course of pharmacotherapy of 54 children with atopic diseases, diseases of the gastrointestinal tract, parasitic infestation, inflammatory diseases of the genital organs, etc. aged from birth to 17 years, who received simultaneously from 5 to 11 drugs (average 6.4 ± 1.5 drugs)
Results. Problematic polypharmacy was founded in 31 children (75.0% of schoolchildren and 38.5% of preschool children) with polypharmacy. Among them, 22 patients (71.0%) had pharmacokinetic risks, and 17 children (54.8%) had pharmacodynamic interactions. Among the causes of pharmacokinetic interaction – the use of inhibitors (omeprazole, etc.) and inducers (phenobarbital, St. John's wort, etc.) metabolism, pharmacodynamic interaction – the simultaneous use of several glucocorticoids, drugs with similar organ toxicity, and more.
Conclusions. Outpatient use of 5 or more drugs is combined in more than half of children at risk of their interaction, development of side effects or reduced effectiveness of treatment.
National Survey of Children’s Health. NSCH 2018 19: Number of Current or Lifelong Health Conditions, Nationwide, Age in 3 Groups. Accessed February 24, 2021.
Publisher Site: https://www.childhealthdata.org/
Huth K, Vandecruys P, Orkin J, Patel H. Medication safety for children with medical complexity. Paediatrics & Child Health. 2020; 25(7):473-474. DOI: 10.1093/pch/pxaa105.
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606167/
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics. 2017;17(1):230. DOI: 10.1186/s12877-017-0621-2.
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635569/
Taghy N, Cambon L, Cohen J-M, Dussart C. Failure to Reach a Consensus in Polypharmacy Definition: An Obstacle to Measuring Risks and Impacts – Results of a Literature Review. Therapeutics and Clinical Risk Management. 2020;16:57-73. DOI: 10.2147/TCRM.S214187.
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023902/
Baker C, Feinstein JA, Ma X, Bolen S, Dawson NV, Golchin N, Horace A, Kleinman LC, Meropol SB, Knight EMP, Winterstein AG, Bakaki PM. Variation of the Prevalence of Pediatric Polypharmacy: A Scoping Review. Pharmacoepidemiol Drug Saf. 2019 March; 28(3): 275-287. DOI:10.1002/pds.4719.
Publisher Site: https://onlinelibrary.wiley.com/doi/10.1002/pds.4719
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461742/
Feinstein JA, Feudtner C, Valuck RJ, Kempe A. The depth, duration, and degree of outpatient pediatric polypharmacy in Colorado fee-for-service Medicaid patients. Pharmacoepidemiol Drug Saf. 2015;24(10):1049-57. DOI: 10.1002/pds.3843.
Publisher Site: https://onlinelibrary.wiley.com/doi/10.1002/pds.3843
Khezrian M, McNeil CJ, Murray AD, Myint PK. An overview of prevalence, determinants and health outcomes of polypharmacy. Ther Adv Drug Saf. 2020; 11: 2042098620933741. DOI: 10.1177/2042098620933741.
Publisher Site: https://journals.sagepub.com/doi/10.1177/2042098620933741
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294476/
Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation. Making it safe and sound. The King’s Fund. 2013. – 56 p.
[Rektodelt 100]. Regulatory and directive documents of the Ministry of Health of Ukraine [in Ukrainian].
Publisher Site: https://mozdocs.kiev.ua/likiview.php?id=813
National transfer of medicinal products «liki control» . [in Ukrainian].
Publisher Site: https://likicontrol.com.ua/
Asher GN, Corbett AH, Hawke RL. Common Herbal Dietary Supplement – Drug Interactions. Am Fam Physician. 2017;96(2):101-107.
Curcumin. DrugBank Accession Number DB11672.
Publisher Site: https://go.drugbank.com/drugs/DB11672
St. John's Wort. DrugBank Accession Number DB01323.
Publisher Site: https://go.drugbank.com/drugs/DB01323
Jeon S-M, Park S, Rhie SJ, Kwon J-W. Prescribing patterns of polypharmacy in Korean pediatric patients. PLoS One. 2019; 14(10): e0222781. DOI: 10.1371/journal.pone.0222781.
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773215/
Drake RE. Overmedicating vulnerable children in the U.S. Epidemiology and Psychiatric Sciences. 2019; 28(4): 358-359. DOI: 10.1017/S2045796018000689
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999034/
Golchin N, Johnson H, Bakaki PM, Dawson N, Knight EMP, Meropol SB, Liu R, Feinstein JA, Bolen SD, Kleinman LC, Horace A. Outcome measures in pediatric polypharmacy research: a scoping review. Drugs Ther Perspect. 2019; 35(9): 447-458. DOI:10.1007/s40267-019-00650-8.
Publisher Site: https://link.springer.com/article/10.1007/s40267-019-00650-8
PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123381/
This work is licensed under a Creative Commons Attribution 4.0 International License.